Anti-IL12 p40/ IL-12B Neutralizing Antibody

IL-12B (Interleukin-12 subunit beta) encodes the p40 subunit of the heterodimeric cytokine IL-12, which functions alongside the p35 subunit (encoded by IL-12A) . The IL12Rβ1 receptor subunit interacts with IL-12B and plays a crucial role in the IL-12 and IL-23 signaling pathways, promoting Th1 cell differentiation and IFN-γ (Interferon-γ) production. Anti-p40 neutralizing antibodies, which target the p40 subunit common to both IL-12 and IL-23, are primarily used as therapeutic agents for autoimmune and inflammatory diseases. These antibodies, such as Ustekinumab, have demonstrated significant efficacy in conditions such as psoriasis, psoriatic arthritis, and Crohn's disease by reducing inflammatory responses and modulating immune activity. The continued exploration of these antibodies holds promise for expanding their use to other immune-related conditions and improving patient outcomes.